Could ACE inhibitors prevent type 2 diabetes in high risk individuals?
A study using data from the HOPE study has suggested that ACE inhibitor treatment in high-risk individuals could reduce the risk of type 2 diabetes. The HOPE study randomised patients with known vascular disease but without overt diabetes to ramipril or placebo for a mean of 4.5 years. Analysis of self-reported diabetes showed that 3.6% developed diabetes in the active group compared to 5.4% in the placebo group. The authors conclude that ramipril was associated with a lower rate of diagnosis than placebo. They caution, however, that the results need confirmation in a prospective study.
